Marksans Pharma is currently trading at Rs. 149.50, up by 2.10 points or 1.42% from its previous closing of Rs. 147.40 on the BSE.
The scrip opened at Rs. 148.05 and has touched a high and low of Rs. 152.10 and Rs. 147.75 respectively. So far 207218 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 185.40 on 18-Apr-2024 and a 52 week low of Rs. 81.51 on 31-May-2023.
Last one week high and low of the scrip stood at Rs. 172.40 and Rs. 144.45 respectively. The current market cap of the company is Rs. 6756.67 crore.
The promoters holding in the company stood at 43.85%, while Institutions and Non-Institutions held 20.74% and 35.40% respectively.
Marksans Pharma has reported results for fourth quarter (Q4) and year ended March 31, 2024.
The company has reported 85.23% rise in its net profit at Rs 32.99 crore for the quarter under review as compared to Rs 17.81 crore for the same quarter in the previous year. Total income of the company increased by 50.87% at Rs 237.39 crore for Q4FY24 as compared Rs 157.35 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 6.13% fall in its net profit at Rs 77.64 crore for fourth quarter ended March 31, 2024 as compared to Rs 82.71 crore for the same quarter in the previous year. However, total income of the company increased by 16.01% at Rs 576.54 crore for Q4FY24 as compared Rs 496.99 crore for the corresponding quarter previous year.
For the year ended March 31, 2024, the company has reported 30.03% rise in its net profit at Rs 133.76 crore as compared to Rs 102.87 crore for the previous year. Total income of the company increased by 27.90% at Rs 915.35 crore for year under review as compared to Rs 715.69 crore for year ended March 31, 2023.
For the year ended March 31, 2024, on the consolidated basis, the company has reported 18.69% rise in its net profit at Rs 314.90 crore as compared to Rs 265.32 crore for the previous year. Total income of the company increased by 16.55% at Rs 2227.83 crore for year under review as compared to Rs 1911.45 crore for year ended March 31, 2023.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1682.55 |
Dr. Reddys Lab | 1091.15 |
Cipla | 1394.85 |
Lupin | 1935.50 |
Zydus Lifesciences | 840.60 |
View more.. |